Clinical Trial

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-13.
Trial Details
NCT Number NCT07710781
Lead Sponsor Ossium Health, Inc.
Conditions Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia +4 more
Enrollment 300 participants
Start Date 2026-12-01
Primary Completion 2029-03-31 (estimated)
Study Completion 2031-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20